A carregar...
Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase...
Na minha lista:
| Publicado no: | J Kidney Cancer VHL |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Codon Publications
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6175852/ https://ncbi.nlm.nih.gov/pubmed/30319937 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15586/jkcvhl.2018.109 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|